Zydus in Exclusive Talks to Acquire Majority Stake in Amplitude Surgical

Varahi media.com online news,India ,March 12, 2025:Zydus Lifesciences Limited (“Zydus”), a leading global life sciences company, has entered into exclusive negotiations to acquire an 85.6% majority stake in Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI), a European MedTech leader specializing in lower-limb orthopedic technologies.

The shares will be acquired from PAI Partners, Amplitude Surgical’s management, and two minority shareholders at €6.25 per share, representing a 80.6% premium over the last closing price on March 10, 2025, and an 88.2% and 92.2% premium over the 3-month and 6-month volume-weighted average price, respectively.

Read this also…“53% of Indians Face Sleep Issues Without a Consistent Bedtime Routine: YouGov & Amazon Alexa Study”

ఇది కూడా చదవండి…ZEE5 మనోరంజన్ ఫెస్టివల్: మార్చి నెలంతా ఉచితంగా బ్లాక్‌బస్టర్ వినోదం!

Read this also…SBI Expands Nationwide, Strengthens Financial Inclusion with 70 New Branches & 501 Women CSPs

Amplitude Surgical is a key player in the European MedTech industry, focusing on the design and development of high-quality knee and hip prostheses. Backed by PAI Partners’ Mid-Market Fund, the company has seen substantial growth in recent years through product innovation, international expansion, and investments in manufacturing and R&D.

For the fiscal year ending June 30, 2024, Amplitude Surgical recorded:

• €106 million in revenue
• €27.1 million in EBITDA under IFRS
• 5% YoY growth for the six months ending December 31, 2024
• 25.4% EBITDA margin (unaudited figures)

Speaking on the acquisition, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, stated:

“Our strong foundation in science, health, and innovation has enabled us to deeply understand patient care pathways. Expanding into MedTech is a natural progression for us. Amplitude Surgical presents strong mid-to-long-term growth opportunities in portfolio expansion, manufacturing, and geographic presence.”

The global medical technology market is valued at over $500 billion, with significant opportunities in implants, medical devices, and diagnostics. Recognized as a high-growth sector by the Government of India, Zydus MedTech is committed to delivering cutting-edge, high-quality solutions backed by advanced R&D and manufacturing capabilities.

Read this also…NSE Clearing Ltd Retains “CRISIL AAA/Stable” Rating for the 17th Consecutive Year

Read this also…ZEE5 Manoranjan Festival Returns: A Month of Free Blockbusters & Festive Entertainment!

Olivier Jallabert, Founder & CEO of Amplitude Surgical, remarked: “We are delighted to join Zydus, a global healthcare leader. This acquisition marks a major milestone for Amplitude Surgical, which has evolved from a national orthopedic challenger to a European leader. We appreciate PAI Partners’ support in our transformation.”

Stefano Drago, Founding Partner, PAI Mid-Market Fund, added: “Amplitude Surgical has strengthened its market position with continuous product innovation, a new state-of-the-art manufacturing facility in France, and an innovative surgical robot. We are pleased to have supported this journey.”

The Block Acquisition remains subject to regulatory approvals and completion of definitive agreements, including authorization from the French Minister of Economy under foreign investment regulations. The deal also includes a reinvestment by Olivier Jallabert, ensuring continuity in leadership.

Following the completion of the Block Acquisition, Zydus will launch a mandatory simplified tender offer for the remaining shares, subject to AMF clearance. The deal is expected to close by June 2025.

Trading of Amplitude Surgical’s stock will resume on March 12, 2025.

About Author